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Background: Advanced glycation endproducts (AGE) and advanced oxidation protein products (AOPP) play a
pivotal role in the development of diabetes associated diseases. The herbal medicines Padma 28 and Padma
Circosan have shown effectiveness in symptoms of diabetes associated diseases and have antioxidant effects. It is
not known whether inhibition of AGE and AOPP formation is a mechanism of their action.
Method: BSA was subjected to glycation or oxidation with or without 70% ethanolic extracts of Padma 28, Padma
Circosan or with an active control. AGE and AOPP concentrations were analyzed fluorimetrically or
spectrophotometrically respectively and by ELISA.
Results: Compared to the positive control Padma 28, Padma Circosan and the active control significantly reduced
AGE levels by 58.6%, 56.7%, and 8.14% (fluorimetry) and by 35.48, 34.19, and 19.68% (ELISA). AOPP were reduced by
57.28/66.78% (30’/60’ incubation), by 67.08/71.99%, and by 81.68/86.54% (spectrophotometry) or by 79.98/86.97%,
79.3/84.3% and 77.07/90.31% (ELISA). All results are significantly different (p < 0.001). No difference was found
between the effects of the two preparations.
Conclusion: Both formulas significantly inhibited the formation of AGE and AOPP to a similar extent as the active
controls. This suggests a possible role for both Padma preparations in the treatment and prevention of diabetes
associated diseases.Background
Diabetic vascular late complications (DVLC) are multi-
factorial diseases that can manifest in different clinical
forms. Together with other factors such as inflammatory
processes and dietary and genetic causes chronic hyper-
glycemia and oxidative stress are the two main factors
causing metabolic disturbances in diabetes mellitus
(DM). They lead to glycation and oxidation of macro-
molecules and tissues, thereby altering their structure
and function. The most known and unfavorable results
of hyperglycemia and oxidative stress are the modifica-
tion of proteins, leading to the formation of advanced
glycation end-products (AGE) and advanced oxidation* Correspondence: ewa.grzebyk@gmail.com
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article, unless otherwise stated.protein products (AOPP). These are being intensively in-
vestigated for their pivotal role both in the pathogenesis
and development of DVLC. AGE and AOPP formations
are important mechanisms among metabolic distur-
bances occurring in diabetes. AGE and AOPP have a
complex structure. They undergo modifications such as
crosslink reactions and accumulation and bind to the
same receptor, the so called receptor for advanced glyca-
tion end products (RAGE), which is the key component
of the intracellular signaling pathways leading to further
metabolic disorders in diabetes. The processes of glyca-
tion and oxidation mutually potentiate and intensify
each others deleterious effects and thus constitute a vi-
cious circlecalled glycoxidation. Glycemic control and
reduction of risk factors of diabetes and its associated
diseases stand at the center of therapeutic strategies.
These are based on lifestyle modification programsd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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logical treatment including oral antihyperglycemic agents
and insulin [1]. However, intensive glucose lowering
showed limited benefits regarding all cause mortality and
deaths from cardiovascular causes in a meta-analysis [2].
In view of these data and considering the importance
of diabetes-associated diseases, an extended therapy and
prevention approach is needed for diabetic patients.
Herbal medicines may play a role in various phases of
such an integrative diabetes management [3]. On the
one hand herbal medicines usually contain numerous
antioxidative substances, which may be helpful in the
prevention of increased oxidative stress and inflamma-
tion as usually occurs in diabetic patients [4-6]. On the
other hand some herbal preparations are known to lower
the blood glucose level, to inhibit AGE formation, pre-
vent acute myocardial ischemic or to have antibacterial
properties [3,5,7-9]. In view of the pivotal role diabetic
complications play in the disease process and mortality
of diabetes such preparations might be highly valuable in
treatment and prevention of DM and its complications.
Among herbal preparations with anti-inflammatory
and anti-oxidant effects there is the Tibetan herbal mul-
ticompound medicine Padma 28. The formula contains
20 plants as well as calcium sulphate and natural cam-
phor and is well-known in Europe since the 19th century
[10]. It has been marketed in Switzerland for the last
35 years and is used in circulatory disorders with symp-
toms such as a tingling sensation, formication, feeling of
heaviness and tension in the legs and arms, numbness of
the hands and feet and calf cramps. An almost identical
formulation is available under the name Padma Circosan
(sometimes also Padma Basic), in different European
countries. The formulas act according to a multi-target
mechanism on different pathogenic factors of athero-
sclerosis [11].
Clinical data have shown Padma 28 to be effective in
micro- and macroangiopathies such as atherosclerotic dis-
eases, e.g. peripheral arterial occlusive disease (PAOD)
and angina pectoris, as well as in symptoms of disturbed
circulation such as paresthesias, pain and swelling in the
extremities and wound healing [12-15]. These symptoms
have a special relevance in diabetic patients.
Various experimental studies suggest a multi-target
mode of action for Padma 28 and Padma Circosan, which,
except the omission of one ingredient (Aconiti tuber), is
identical to Padma 28. Among others the anti-oxidative
and anti-inflammatory properties are mentioned. Padma
28 was found to be a strong iron chelator and radical scav-
enger [16]. Furthermore, Padma 28 inhibited lipid peroxi-
dation [17] and protected LDL from oxidation [18].
These data as well as clinical case reports in diabetes
caused paresthesias and polyneuropathia [19,20] support
the use of Padma 28 and Padma Circosan in diabetesand diabetes associated diseases. However, nothing is
known about their effect on AGE and AOPP formation.
The aim of the current study was to examine, whether
these herbal preparations are able to inhibit the forma-
tion of AGE and AOPP in vitro and if so, whether there
is a difference between the activities of these two
formulas.
Methods
Test substances and materials
Padma 28 and Padma Circosan were produced according
to good manufacturing practice by Padma Inc. in
Switzerland. They were provided as raw powder without
excipients and contain calcium sulphate, natural camphor
and 20 or 19 herbal drugs respectively. The composition
of Padma 28 has been published previously [21].
In this study, 400 mg herbal powder were suspended
in 2 ml of 70% ethanol and shaken at 37°C for 30 mi-
nutes. The solutions were centrifuged for 15 min at
2200 rpm and the supernatants were filtered through
0.22 um filter (Millipore, USA). Bovine serum albumin
(BSA) was used as model protein, which was glycated
and oxidated in two individual studies. BSA was used in
a concentration of 40 mg/mL, which corresponds to the
physiological concentration of albumin in human blood.
As a negative control (C-) BSA was dissolved in PBS
(pH 7.4), and as a positive control (C+) BSA was incu-
bated with glucose or chloramine as appropriate for the
process of glycation and oxidation of proteins. All re-
agents used in the study were from Sigma (USA). The
glucose and chloramine concentrations were chosen
based on previous studies. Experiments were performed
in different concentrations of extracts and the amount
of extracts used was chosen for the optimal readability
in the detection methods appliedd. The experiments
were performed in three series, each time in triplicate.
Each sample was sealed in a separate flask, and all were
incubated in Heidolph Polymax 1040 device at 50 rpm
in a darkened room.
Glycation
BSA was incubated with 500 mg/mL glucose for eight
weeks at 37°C (positive control C+) or with PBS alone as
negative control (C-). For the actual test Padma 28 and
Padma Circosan extracts were added 0.8/8 (v/v) and for
the active control aminoguanidine (A, 50 mM), a known
inhibitor of protein glycation, was used.
Every week, samples of 0.8 mL were collected. After
48 hours of dialysis in PBS with a one-time exchange of
solution after 24 hours, the samples were frozen at −80°C
for future analysis. The level of advanced glycation end
products (AGE) was measured fluorimetry with the modi-
fied method described by Munch et al. [22,23]. Briefly the
characteristic fluorescence with excitation at 370 nm was
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Elmer LS50B. The results were converted into arbitrary
fluorescence units (AFU) according to the formula:
AGE AFUð Þ ¼ FxRð Þ  V1=V2ð Þ
where:
F - measured fluorescence intensity of the sample
R - dilution of the sample (R = 500)
V1 - volume of the cuvette in μL (V1 = 1000)
V2 - sample volume in μL (V2 = 20)
To determine the AGE concentration with the immu-
noenzymatic method the OxiSelect Advanced Glycation
End Products (AGE) ELISA test (CELL BIOLABS, INC,
San Diego USA) was used. The test was performed ac-
cording to the manufacturer's instructions, with the use
of appended reagents and was read on Stat Fax 2100
spectrometer (Awareness Technology, Inc., USA) at a
wavelength of 450 nm and 630 nm differential filters.
Oxidation
BSA was incubated with chloramine T (20 mM, positive
control C+) for 60 minutes at 37°C or with PBS alone
(negative control C-). The test substances were added in a
final concentration of 0.8/8 (v/v), vitamin C, as a known
inhibitor of protein oxidation, was used as an active con-
trol (10 mM).
After 30 minutes, a first set of samples of 0.8 mL was
collected. After 48 hours of dialysis in PBS, with one ex-
change of solution after 24 hours, all samples were fro-
zen at -80°C for future analysis.
The level of advanced oxidation protein products (AOPP)
was measured to assess the degree of albumin oxidation.
The spectrophotometry method described by Witko-Sarsat
et al. [24] was applied. The measurement of AOPP is based
on their reaction with potassium iodide in the presence of
acetic acid. The derivatives were measured spectrophoto-
metrically at 340 nm. For the calculation of the concentra-
tion of AOPP a calibration curve was generated using
increasing concentrations of chloramine-T solution as re-
agent for iodination and the following formula was applied:
AOPP concentration : C μM½  ¼ 1 = B  A  R
where:
C - concentration of AOPP in the material
A - absorbance measured at a wavelength of λ = 340 nm
R - coefficient taking account into dilution (R = 0.70922)
B - slope of the calibration curve (B = 0.0141).
To determine AOPP concentration by the immu-
noenzymatic method the AOPP Kit (Immun Diagnostic,
Benshein Germany) was used. The test was performed ac-
cording to the manufacturer's instructions and was read
on the Stat Fax 2100 spectrophotometer at a wavelength
of 340 nm and 630 nm differential filters. All experimentswere performed first with a blank to assess whether the
red color of the extract influenced the test readings. This
was only the case in the ELISA measurements of AOPP.
These results were corrected accordingly with the read-
ings of the blanks.
All tests were run in duplicate (controls) or triplicate
(test substances) and the experiments were each re-
peated twice, the data are reported as the mean ± SEM.
Statistical analysis
The results were statistically analyzed using paramet-
ric tests. The presented results obtained from the ana-
lysis of Student’s t-test in Statistica PL (version 10.0). A
p-value of < 0.05 was regarded as statistically significant.
Results
Glycation process
The ethanolic extracts of both Padma 28 and Padma
Circosan as well as the active control inhibited the for-
mation of AGE significantly as measured fluorimetrically
as well as by ELISA. In the fluorimetric analysis the level
of AGE in the samples of glycated BSA albumin (positive
control C+) was significantly higher than non glycated
BSA albumin (negative control C-) from week 1 and was
6.69 times higher at week 8 (p < 0.001, Figure 1, Figure 2).
All three substances (the active control aminoguanidine,
Padma 28 and Padma Circosan) showed an inhibitory ef-
fect on protein glycation (significantly from week 2). Both
the test substances showed an almost identical level of gly-
cated proteins as the active control. Compared to C + the
AGE after 8 weeks of incubation were reduced by 58.14%
(aminoguanidine), 58.6% (Padma 28) and 56.688% (Padma
Circosan, all p < 0.001, Figure 2).
For confirmation of these data AGE concentrations
were analyzed also with ELISA and the results expressed
as mean ± SEM of all 3 test series (Figure 3). Due to the
low sensitivity of the test reliable data could only be ob-
tained at 8 weeks of incubation.
The concentration of AGE in the positive control (C+)
was 6.38 times higher than in the negative control (C-,
p < 0.001). Compared to C + aminoguanidine, Padma 28
and Padma Circosan showed a significant inhibitory effect
on protein glycation and thus lower concentrations of
AGE (p < 0.001). While aminoguanidine inhibited AGE
formation by 19.68%, Padma 28 by 35.48% and Padma
Circosan inhibited it significantly more by 34.19% respect-
ively (both p < 0.001 compared to C + and to A).
No statistically significant difference was found be-
tween Padma 28 and Padma Circosan, neither with the
fluorimetric method nor with ELISA.
Oxidation process
Both Padma 28 and Padma Circosan as well as the active
control (vitamin C) inhibited the formation of AOPP
Figure 1 The inhibition of the formation of AGE by Padma 28, Padma Circosan and the active control aminoguanidine over the
8 weeks of incubation as measured fluorimetrically.
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ELISA test (Figures 4 and 5).
The concentration of AOPP as analyzed with spectro-
photometry was 150.33 and 149.22 times higher in the
positive control C+ than in the negative control C- after
30 minutes or 60 minutes of incubation respectivelyFigure 2 The concentration of AGE [AFUx105] measured fluorimetrica
three series in triplicate each, data are presented as the mean ± SEM.(both p < 0.001). The active control vitamin C as well as
the test substances Padma 28 and Padma Circosan
showed an inhibition of BSA oxidation by 81.68% and
86.54%, by 57.28% and 66.78%, and by 67.08% and
71.99% after 30 or 60 minutes respectively (Figure 4, all
p < 0.001 compared to C+). The difference betweenlly after 8 weeks of incubation. Experiments were conducted in
Figure 3 The concentration of AGE [μg/ml] measured by ELISA after 8 weeks of incubation.
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nificant at both incubation times (p < 0.001), but not be-
tween Padma 28 and Padma Circosan.
These results were confirmed by measurements of
AOPP concentrations with the ELISA kit. The results of
the BSA oxidation are expressed as means ± SEM of all 3
Series after 30 and 60 minutes of incubation (Figure 5).Figure 4 The concentration of AOPP after 30 and 60 minutes of oxidaThe results show that the concentration of AOPP in
the positive control is 29.0 and 47.8 times higher than in
the negative control after 30 or 60 minutes of incubation
respectively (both p < 0.001). Vitamin C, Padma Circosan
and Padma 28 reduced the oxidation of BSA by 77.07%
and 90.31%, by 79.98% and 86.97%, and by 79.3% and
84.3% after 30 or 60 minutes respectively (all p < 0.001).tion measured spectrophotometrically.
Figure 5 The concentration of AOPP after 30 and 60 minute of oxidation measured with ELISA.
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tween the active control and the two test substances.
Discussion
The prevalence of diabetes mellitus type 2 and therewith
also of diabetes-associated diseases is growing globally.
Nearly 350 million people (about 3,8% of the population)
suffer from diabetes and 70% to 80% of diabetic patients
eventually die because of diabetes-associated diseases and
DVLC, especially cardiovascular disorders [25,26]. Al-
though these are multifactorial diseases involving among
others genetic, dietary, life-style factors, and immunologic
pathogenic processes, AGE and AOPP formed as a results
of chronic hyperglycemia as well as oxidative stress are
pivotal in metabolic disturbances occurring in diabetes.
Glycation and oxidation processes also occur at low
levels in healthy people and naturally increase with ad-
vancing age, but the increase is much steeper in dia-
betes patients, even if hyperglycemia is well controlled
[27]. Accelerated glycoxidative modifications of macro-
molecules, especially proteins, are a major factor lead-
ing to damage of blood vessels and nerves, finally
resulting in micro- and macroangiopathies and others
diabetes-associated disturbances [3,27].
AGE are a heterogeneous group of molecules formed
from the non-enzymatic reaction between reducing
sugars and free amino groups of proteins, lipids or nu-
cleic acids. The first product of this reaction is a Schiff
base, which spontaneously rearranges itself into an Ama-
dori product. These initial reactions are reversible de-
pending on the concentration of the reactants. Then aseries of subsequent reactions, including dehydrations,
oxidation-reduction reactions, fragmentation and other
re-arrangements lead to the formation of AGE. One char-
acteristic of AGE is their ability to form covalent crosslink
formations between proteins e.g. cellular matrix proteins,
basement membrane proteins, and vessel-wall compo-
nents, a process which alters their structure and function.
Another important feature of AGE is their interaction
with RAGE receptors, which are presented on the surface
of a variety cells and which leads either to their endocyto-
sis and degradation or to cellular activation and pro-
oxidant, pro-inflammatory events [22,27].
AOPP are also a heterogeneous group of molecules
originating as a result of the action of free radicals on
proteins, especially albumin and lipoproteins. Chlor-
amine, hypochlorous acid- myeloperoxidase-H2O2-halide
system of activated phagocytes are the main agents par-
ticipating in AOPP formation in-vivo. The structure of
AOPP shows a large similarity to that of AGE. Moreover,
like AGE, AOPP can react with RAGE receptors, accumu-
late in tissues and act as inflammatory mediators trigger-
ing the oxidative stimulation of neutrophils, monocytes
and T-lymphocytes, thus leading to their upregulation
through a positive-feedback mechanism [28,29]. Increased
AGE and AOPP formation and accumulation in the vas-
cular tissues have been associated with changes in endo-
thelial cells and function. They are the protagonists in the
pathogenesis of diabetes associated diseases and contrib-
ute to the DVLC such as hypertension, dyslipidemia and
low-level inflammation [29,30]. Thus, prevention of exces-
sive formation of AGE and AOPP seems to be a very
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diabetes and the prevention of diabetes associated
diseases.
In our study, using bovine serum albumin (BSA) as a
model protein, the antiglycoxidative properties of Padma
28 and Padma Circosan were analyzed. We revealed
strong inhibitory effects of both formulas on AOPP as
well as on AGE formation. No difference was found be-
tween the activities of these two preparations. Interest-
ingly, the anti-glycative effects of Padma 28 and Padma
Circosan seem to be of a similar magnitude as that of
the active control aminoguanidine. This was confirmed
both by the fluorimetric as well as by the ELISA method.
The anti-glycative effects of Padma 28 and Padma Circo-
san as determined by the immunoenzymatic test were
even stronger than the effect of aminoguanidine com-
pared to the results obtained fluorimetrically. The differ-
ence between the two methods may result from the high
specificity of the ELISA assay. The results show that
Padma Circosan and Padma 28 inhibit the glycation
process to a similar degree and they show only a slightly
stronger inhibitory effect than aminoguanidine, indicat-
ing a very strong anti-glycative activity of both formulas.
The results determined by the spectrometric method
show strong inhibitory effects of Padma Circosan and
Padma 28 on the oxidation process, thus providing fur-
ther evidence of their anti-oxidant activity. After 30 min
of oxidation Padma Circosan and Padma 28 show a
similar level of inhibition on the protein oxidation
process as vitamin C, whereas after 60 minutes the in-
hibitory effect of vitamin C was more pronounced. How-
ever, even after 60 minutes of oxidation Padma Circosan
and Padma 28 still show a strong potential to counteract
the oxidation of proteins. An extrapolation of these re-
sults gained in a cell-free in vitro setting to the clinical
situation is not possible. First clinical data from single
case reports have to be supplemented with further stud-
ies to determine the clinical relevance of the effects
found in these experiments.
Although vitamin C, functioning as an active control
in our experiments, has a known strong antioxidative
potential and an inhibiting effect on AOPP formation
in vitro, the results of clinical trials with vitamin C in
diabetic complications are equivocal [31]. One reason
for this could be that for an effective detoxification of
oxidative stress in the organism a well functioning anti-
oxidative network is needed, in which a variety of antioxi-
dant agents of different strengths as well as enzymatic
antioxidants and an intrinsic recycling process and the re-
generation of the antioxidant capacity of the system work
together. The increase of one of these elements alone, e.g.
vitamins C or E, cannot uphold the antioxidative capacity
of the system. Because they contain many different antiox-
idative compounds and, as is the case for Padma 28,additionally activate antioxidative signaling pathways,
herbal substances are much better suited in this compli-
cated multifactorial events [32,33].
Conclusion
In summary, the results clearly show strong anti-
glycative and anti-oxidative effects of Padma 28 as well
as Padma Circosan, which are of a similar order than
the standard active controls. Moreover, the present study
shows that both preparations are able to protect albumin
from detrimental oxidative and glycative modification.
This is evidence of a so far unknown mode of action
which, additionally to the symptomatic treatment of cir-
culatory disorder in general, suggests a special benefit in
patients with diabetes. The inhibition of AGE and AOPP
formation, causative mechanisms in the development of
diabetes associated diseases, thus suggest a possible role
of Padma 28 and Padma Circosan in an integrative dia-
betes management, not only as a treatment of specific
circulatory symptoms, but also more generally in the
prevention of diabetes associated diseases.
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